Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants

Transplantation

Volumn 97, Issue 5, 2014, Pages 541-547

  Sharif, Adnan ^a   Kraus, Edward S ^b   Zachary, Andrea A ^b   Lonze, Bonnie E ^b   Nazarian, Susanna M ^b   Segev, Dorry L ^b   Alachkar, Nada ^b   Arend, Lois J ^b   Bagnasco, Serena M ^b   Racusen, Lorraine C ^b   Montgomery, Robert A ^b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

ABO incompatible; Desensitization; Histopathology; HLA incompatible; Incompatible transplantation; Kidney transplantation; Protocol biopsy

Indexed keywords

COMPLEMENT COMPONENT C4D;

ADULT; ARTICLE; CAPILLARITIS; CONTROLLED STUDY; FEMALE; GLOMERULITIS; GLOMERULOPATHY; GRAFT SURVIVAL; HISTOPATHOLOGY; HLA INCOMPATIBLE KIDNEY TRANSPLANTATION; HUMAN; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROCIRCULATION; NEPHRITIS; OUTCOME ASSESSMENT; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

ADULT; ALLOGRAFTS; BIOPSY; COMPLEMENT C4B; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PHENOTYPE; PREVALENCE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84896316325     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442513.27641.7e     Document Type: Article

References (23)

1. Montgomery RA,Warren DS, Segev DL, et al. HLA incompatible renal transplantation. Curr Opin Organ Transplant 2012; 17: 386
2. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLAincompatible kidney recipients and survival. N Engl J Med 2011; 365: 318
3. Stegall MD, Gloor JM. Deciphering antibody-mediated rejection: New insights into mechanisms and treatment. Curr Opin Organ Transplant 2010; 15: 8
4. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046
5. Sharif A, Alachkar N, Kraus E. Incompatible kidney transplantationVa brief overview of the past, present and future. QJM 2012; 105: 1141
6. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9: 2561
7. Haas M,Montgomery RA, Segev DL, et al. Subclinical acute antibodymediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7: 576
8. Halloran PF, De Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology, and outcomes in kidney transplants. Am J Transplant 2010; 10: 2223
9. Tinckam KJ, Djurdjev O, Magil AB. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int 2005; 68: 1866
10. Loupy A,Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11: 56
11. Locke JE, Zachary AA, Warren DS, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9: 2136
12. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12: 1168
13. De Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with De novo donor-specific antibodies. Am J Transplant 2013; 13: 485
14. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684
15. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76
16. Kieran N, Wang X, Perkins J, et al. Combination of peritubular C4d and transplant glomerulopathy predicts late renal allograft loss. J Am Soc Nephrol 2009; 20: 2260
17. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: Chronic humoral rejection, hepatitis C infection, and thromboticmicroangiopathy. Kidney Int 2011; 80: 879
18. Stegall MD, Diwan T, Raghavalah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405
19. Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8: 670
20. Haas M, Mirocha J. Early ultrastructural changes in renal allografts: Correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant 2011; 11: 2123
21. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887
22. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753
23. Bagnasco SM, Tsai W, Rahman MH, et al. CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. Am J Transplant 2007; 7: 1968 Kidney Diseases Kidney Diseases